In a major breakthrough in the fight against COVID-19 and influenza, the European Medicines Agency (EMA) has recommended the approval of Moderna’s combined mRNA vaccine, mCombriax, for use in the European Union (EU). This is the first time a combined respiratory viral vaccine has been recommended for market authorization in the EU, highlighting the agency’s confidence in the safety and effectiveness of this innovative vaccine.
The EMA’s recommendation comes after a thorough evaluation of scientific data from Moderna’s clinical trials, which have shown promising results in preventing both COVID-19 and influenza. This combined vaccine, developed by Moderna in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) in the United States, targets the spike protein of the viruses, making it a potent weapon against both respiratory illnesses.
mCombriax is based on Moderna’s successful mRNA technology, which has already proven its efficacy in the company’s authorized COVID-19 vaccine. This technology works by delivering genetic instructions to the body’s cells, allowing them to produce a harmless piece of the virus’s protein. This triggers an immune response, preparing the body to fight the virus if it encounters the real thing in the future.
EMA’s Executive Director, Emer Cooke, commented on the agency’s recommendation, saying, “This is a significant step forward in our fight against COVID-19 and influenza. The combined mRNA vaccine has shown impressive results in clinical trials and has the potential to protect people from two respiratory viruses at once.” She also added that this recommendation is in line with the EMA’s mission to ensure timely access to safe and effective medicines for EU citizens.
According to the EMA, mCombriax is recommended for use in individuals aged 18 years and above, with two doses administered four weeks apart. The agency also states that the vaccine should be given as a booster dose for individuals who have already received a COVID-19 vaccine, providing them with additional protection against influenza.
The decision to approve mCombriax was based on the positive results from Moderna’s Phase 2/3 clinical trials, which involved over 17,000 participants. The trials showed that the combined vaccine was highly effective in preventing both COVID-19 and influenza. In addition, the vaccine’s safety profile was similar to that of Moderna’s authorized COVID-19 vaccine, with mild to moderate side effects reported, such as pain at the injection site, fatigue, and headache.
This recommendation from the EMA is a significant milestone for Moderna, as it marks the first time the company’s combined mRNA vaccine has been granted market authorization. Stéphane Bancel, Moderna’s Chief Executive Officer, expressed his gratitude towards the EMA for their thorough evaluation and recommendation. He also highlighted the potential of mCombriax to have a positive impact on public health, saying, “We are proud to be at the forefront of innovation and believe that mCombriax has the potential to make a meaningful difference in the global fight against COVID-19 and influenza.”
In conclusion, the EMA’s recommendation of mCombriax is a major step forward in the battle against COVID-19 and influenza. This combined mRNA vaccine has shown promising results in clinical trials and has the potential to provide enhanced protection against two respiratory viruses. With the EMA’s endorsement, mCombriax is now one step closer to being available for use in the EU, bringing us one step closer to the end of this pandemic.
